Vertex Pharmaceuticals (NQ:VRTX)

504.73 -2.01 (-0.40%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 27, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals...

Via Benzinga

Vertex to Participate in Upcoming September Investor Conferences

August 26, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Large-Cap Stocks to Research Further and 1 We Question

August 26, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Via StockStory

Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide ↗

August 24, 2026

Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.

Via The Motley Fool

Topics Economy Intellectual Property

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗

July 29, 2026

Via Chartmill

Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗

July 21, 2026

Via Chartmill

Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? ↗

August 21, 2026

Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.

Via The Motley Fool

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗

August 21, 2026

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Via The Motley Fool

Topics ETFs Stocks

Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ ↗

August 21, 2026

CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).

Via Benzinga

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗

August 20, 2026

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Via The Motley Fool

3 Cash-Producing Stocks on Our Watchlist

August 18, 2026

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ...

Via StockStory

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

August 14, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals...

Via Benzinga

Vertex (VRTX) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

Revenue hit $3.3 billion with guidance raised on strong newer product growth.

Via The Motley Fool

Topics Earnings

Discover which S&P500 stocks are making waves on Monday. ↗

August 10, 2026

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

August 10, 2026

Via Chartmill

Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗

August 10, 2026

Via Chartmill

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

August 10, 2026

Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfol...

Via StockStory

Topics Earnings

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗

August 07, 2026

This risk is weighing on the stock.

Via The Motley Fool

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday ↗

August 04, 2026

The company notched a pair of modest beats in its second quarter.

Via The Motley Fool

Vertex Pharmaceuticals Q2 Earnings Call Highlights ↗

August 03, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising...

Via MarketBeat

Topics Earnings

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations

August 03, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. ...

Via StockStory

Vertex Reports Second Quarter 2026 Financial Results

August 03, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

August 01, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for. Vertex Pharmaceuticals be...

Via StockStory

Topics Artificial Intelligence

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗

July 30, 2026

There are other reasons to pay attention to Viking Therapeutics.

Via The Motley Fool

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗

July 30, 2026

The next six months may be decisive for the biotech.

Via The Motley Fool

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

July 29, 2026

From AbCellera Biologics Inc.

Via Business Wire

3 Healthcare Stocks with Competitive Advantages

July 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)

July 21, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗

July 19, 2026

The biotech's diversification efforts continue.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.